Genaissance Enters Pharmacogenomic Collaboration with Otsuka
News Sep 30, 2005
Genaissance Pharmaceuticals, Inc. has announced that it has entered into a pharmacogenomic research collaboration with Otsuka Pharmaceutical Co., Ltd.
Under the terms of the agreement, Genaissance will apply its HAP™ Technology with the goal of identifying genetic markers related to drug response.
Genaissance and Otsuka will be co-owners of the intellectual property that results from the collaboration and both companies will be eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.
"We are very pleased that we will be collaborating with Otsuka," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals.
"We believe this agreement is another indication that pharmacogenomics is becoming an important tool for drug development."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.